S100 protein in breast tumor

Li, F; Men, Xiaojuan; Zhang, W

doi:10.4103/0019-509x.154046

Cited by 17 publications

(6 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Breast cancer is the most common cancer type among women [79], and especially metastatic breast cancers are highly lethal [80]. It was shown that several S100 family members, including S100A2, S100A4, S100A6, S100A7, S100A8, S100A9, and S100A11 are up-or downregulated in breast cancer compared with healthy tissue, suggesting that S100 proteins play a crucial role in tumour development and progression [81,82] and as predictive biomarkers [83][84][85][86][87][88].…”

Section: S100 Proteins In Breast Cancermentioning

confidence: 99%

“…The interaction between S100A4 and matrix metalloproteinase 2 (MMP2) induces epithelial-mesenchymal transition (EMT), which is considered to be an initial step during invasion and metastasis [95]. S100A4 can not only be found in cancer cells but is also highly expressed in stromal cells of the tumour microenvironment (TME), such as fibroblasts, T-cells, macrophages, and neutrophils [81,96]. Extracellular S100A4 in the TME induces the release of pro-inflammatory factors (e.g., interleukin 6 (IL-6), interleukin 8 (IL-8), and C-X-C motif chemokine 10 (CXCL10)), which then converts monocytes into tumour-associated macrophages (TAMs), resulting in metastasis and drug resistance [97].…”

Section: S100 Proteins In Breast Cancermentioning

confidence: 99%

See 1 more Smart Citation

Friend or Foe: S100 Proteins in Cancer

Allgöwer

Kretz

Karstedt

et al. 2020

Cancers

View full text Add to dashboard Cite

S100 proteins are widely expressed small molecular EF-hand calcium-binding proteins of vertebrates, which are involved in numerous cellular processes, such as Ca2+ homeostasis, proliferation, apoptosis, differentiation, and inflammation. Although the complex network of S100 signalling is by far not fully deciphered, several S100 family members could be linked to a variety of diseases, such as inflammatory disorders, neurological diseases, and also cancer. The research of the past decades revealed that S100 proteins play a crucial role in the development and progression of many cancer types, such as breast cancer, lung cancer, and melanoma. Hence, S100 family members have also been shown to be promising diagnostic markers and possible novel targets for therapy. However, the current knowledge of S100 proteins is limited and more attention to this unique group of proteins is needed. Therefore, this review article summarises S100 proteins and their relation in different cancer types, while also providing an overview of novel therapeutic strategies for targeting S100 proteins for cancer treatment.

show abstract

Section: S100 Proteins In Breast Cancermentioning

confidence: 99%

Section: S100 Proteins In Breast Cancermentioning

confidence: 99%

Friend or Foe: S100 Proteins in Cancer

Allgöwer

Kretz

Karstedt

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…In recent years, reviews on the role of the S100 protein family in various types of cancers, e.g., breast [34] , [35] , pancreatic [27] , colorectal [22] , and lung cancer [36] , have been published. This review aims to address the role of S100 proteins in hematological malignancies, with a special focus on AML.…”

Section: The S100 Protein Familymentioning

confidence: 99%

S100 Proteins in Acute Myeloid Leukemia

Brenner

Bruserud

2018

Neoplasia

View full text Add to dashboard Cite

The S100 protein family contains 20 functionally expressed members, which are commonly dysregulated in cancer. Their wide range of functions includes cell proliferation, cell differentiation, regulation of transcription factors, inflammation, chemotaxis, and angiogenesis. S100 proteins have in several types of cancer proven to be biomarkers for disease progression and prognosis. Acute myeloid leukemia (AML) is a highly heterogeneous and aggressive disease in which immature myeloblasts replace normal hematopoietic cells in the bone marrow. This review focuses on the S100 protein family members, which commonly are dysregulated in AML, and on the consequences of their dysregulation in the disorder. Like in other cancers, it appears as if S100 proteins are potential biomarkers for leukemogenesis. Furthermore, several S100 members seem to be involved in maintaining the leukemic phenotype. For these reasons, specific S100 proteins might serve as prognostic biomarkers, especially in the patient subset with intermediate/undetermined risk, and as potential targets for patient-adjusted therapy. Because the question of the most suitable candidate S100 biomarkers in AML still is under discussion, because particular AML subgroups lead to specific S100 signatures, and because downstream effects and the significance of co-expression of potential S100 binding partners in AML are not fully elucidated yet, we conclude that a panel of S100 proteins will probably be best suited for prognostic purposes.

show abstract

“…The name was a result of their solubility in 100% saturated ammonium sulphate [4]. There are currently 25 known members of the S100 family, which are tissue-specific [2,5,6]. This protein family has important intracellular and extracellular roles.…”

Section: S100 Protein Familymentioning

confidence: 99%

A Promising Novel Biomarker For Embryogenesis and Carcinogenesis: S100P Protein

Görmüş¹

2018

Int J Med Biochem

View full text Add to dashboard Cite

INTERNATIONAL JOURNAL OF MEDICAL BIOCHEMISTRY Objectives: Over the past decade, many great improvements have been achieved in cancer detection. Although there are many cancer biomarkers in use, unfortunately most of these biomarkers cannot yet be used efficiently for clinical purposes. Novel and reliable biomarkers are still required for the early detection and prognosis prediction of cancer. In many aspects, S100 calcium-binding protein P (S100P), a protein that is encoded by the S100P gene, is an interesting and promising marker that can enable the detection of many aggressive cancers in the early stages. S100P overexpression seems to be related to cancer aggression because of its capability to promote cell proliferation, invasion, and migration. Once we understand the molecular mechanisms better, S100P may be used as a specific biomarker and even a potential drug target for various cancers. The S100P protein is discussed in this review in relation to its functions and possible usage in the clinical area, mainly focusing on potential use in cancer research.

show abstract

S100 protein in breast tumor

Cited by 17 publications

References 82 publications

Friend or Foe: S100 Proteins in Cancer

Friend or Foe: S100 Proteins in Cancer

S100 Proteins in Acute Myeloid Leukemia

A Promising Novel Biomarker For Embryogenesis and Carcinogenesis: S100P Protein

Contact Info

Product

Resources

About